PROMENADE: Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions

Sponsor
Azienda Ospedaliera Città della Salute e della Scienza di Torino (Other)
Overall Status
Completed
CT.gov ID
NCT03436940
Collaborator
(none)
802
1
2
16.4
48.9

Study Details

Study Description

Brief Summary

The purpose of this study is to improve discharge planning effectiveness by comparing two strategies [on-Demand Discharge Planning (DDP) vs. Routine Discharge Planning (RDP)], in terms of reduction of hospital readmissions for inpatients classified at intermediate risk of complex discharge using the simplified Blaylock Risk Assessment Screening Score (BRASS).

Condition or Disease Intervention/Treatment Phase
  • Other: On Demand Discharge Planning (DDP)
  • Other: Routine Discharge Planning (RDP)
N/A

Detailed Description

The purpose of this study is to improve discharge planning effectiveness by comparing two strategies [on-Demand Discharge Planning (DDP) vs. Routine Discharge Planning (RDP)], in terms of reduction of hospital readmissions for inpatients classified at intermediate risk of complex discharge using the simplified Blaylock Risk Assessment Screening Score (BRASS).

Five Internal Medicine Unit and four Units of Neurology will be randomized to the two different strategies of discharge planning (RDP or DDP), based on two different alternating sequences of four periods (each period comprising three months). The randomization will be stratified by type of unit.

Patients at risk of complex discharge, according to the simplified BRASS score, are assigned to the Hospital Unit of Continuity of Care (NOCC) team, using the hospital telematics system. Afterwards, the NOCC team proposes an appropriate discharge planning, considering clinical and social needs.

Study Design

Study Type:
Interventional
Actual Enrollment :
802 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
cluster randomized cross-over trialcluster randomized cross-over trial
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions: A Cluster Randomized Cross-over Trial
Actual Study Start Date :
Jun 1, 2018
Actual Primary Completion Date :
Oct 12, 2019
Actual Study Completion Date :
Oct 13, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: On Demand Discharge Planning (DDP)

Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.

Other: On Demand Discharge Planning (DDP)
Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.

Experimental: Routine Discharge Planning (RDP)

All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)

Other: Routine Discharge Planning (RDP)
All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)

Outcome Measures

Primary Outcome Measures

  1. Unexpected hospital readmission within 90 days from discharge [90 days]

    Proportion of hospital admissions in the standard admission regime within 90 days from the date of discharge. The endpoint will be calculated only for patients discharged alive. Readmissions for any cause under ordinary admissions will be considered as event. The Day Hospital re-admissions will not be considered for the endpoint calculation.

Secondary Outcome Measures

  1. Proportion of Long Length of Stay (LLOS) [150 days]

    Proportion of admissions with long duration of hospitalization (LLOS - Long Length of Stay). The endpoint will be calculated for all hospitalized patients. An admission will be considered as LLOS if its duration will be higher than the 90th specific percentile for Diagnostic Related Group (DRG ) detected at the regional level in Piedmont in 2016.

  2. Death within 90 days from discharge [90 days]

    Proportion of deaths within 90 days of discharge date. The endpoint will be calculated only for patients discharged alive. Death for any cause will be considered as event.

  3. Proportion of patients reported to the NOCC team during the DDP-experimental phase [150 days]

    Incidence of activations of the NOCC in the periods of adoption of the DDP strategy (only for admissions treated with DDP strategy)

  4. Healthcare costs until 90 days from the discharge [90 days]

    Health care costs charged to the National Health Service (NHS) between the date of admission and 90 days from the date of discharge or death of the patient.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults patients (age ≥ 18 years);

  • Residents in Piedmont, Italy;

  • Patients admitted to General Internal Medicine or Neurology Units of Molinette Hospital (Turin)

  • Patients with a score in the simplified BRASS between 4 and 6 at admission

No specific exclusion criteria were applied.

Contacts and Locations

Locations

Site City State Country Postal Code
1 AOU Città della Salute Torino Italy 10100

Sponsors and Collaborators

  • Azienda Ospedaliera Città della Salute e della Scienza di Torino

Investigators

  • Principal Investigator: Daniela Corsi, MD, Azienda Ospedaliera Città della Salute e della Scienza di Torino

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniela Corsi, MD, Director of "SSD Integrazione Ospedale-Territorio", Azienda Ospedaliera Città della Salute e della Scienza di Torino
ClinicalTrials.gov Identifier:
NCT03436940
Other Study ID Numbers:
  • CS2/378/2017
First Posted:
Feb 19, 2018
Last Update Posted:
Mar 29, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Mar 29, 2022